In its final brief submitted to the US Supreme Court on March 31, 2017, Sandoz asked the Court to reverse the decision of the US Court of Appeals for the Federal Circuit on the Biologics Price Competition and Innovation Act (BPCIA), issued on July 21, 2015. The dispute (Sandoz, Inc. v. Amgen, Inc. and Amgen, Inc. v. Sandoz, Inc., U.S., Nos. 15-1039 and 15-1195) concerns Sandoz’s filgrastim-sndz (Zarxio), biosimilar to Amgen’s filgrastim (Neupogen), and the companies’ dist inctinterpretations of the portion of the BPCIA that created a faster pathway of approval for biosimilars. The Court’s decision will likely affect how quickly biosimilars are released to the US market and how long innovators can remain the sole marketer of the drug.
Sandoz’s brief states that “Sandoz agrees with Amgen that the Biosimilars Act should be applied ‘as written.’ But that means applying the statute as written in its entirety—not just the parts Amgen rips from context and reads in isolation.” At issue are 2 BPCIA provisions, one of which requires the biosimilar applicant to give the biologic reference product sponsor (RPS) its biosimilar application and manufacturing information and to work with the sponsor on a list of the RPS patents that might be infringed; the other requires the applicant to give the RPS notice 180 days before it intends to start selling the biosimilar.
The Federal Circuit court awarded a split decision, with each side winning on 1 issue. It agreed with Sandoz and the district court that the exchange of information was optional, but disagreed with its ruling on the 180-day notice, agreeing with Amgen that the statute means the applicant can’t give notice of commercial marketing until after the FDA has approved the biosimilar for marketing, therefore delaying Zarxio’s release for 6 months.
Sandoz petitioned and Amgen cross-petitioned the Supreme Court for review. Each party requesting that the Court reverse what was unfavorable to them. The Court granted both petitions review and each side submitted opening and reply briefs.
Sandoz’s reply brief said the BPCIA, as written by Congress, lays out different routes to resolving litigation and specific consequences. Sandoz said that each step specified in the Act was a mandatory condition precedent to continuing the process, and contends that Amgen’s interpretation of the BPCIA disregards the statute’s consequences for not following them. Sandoz said it was not Congress’s intention to inject a second timing element into the statute— that there be no notice until after FDA approval. Furthermore, Sandoz said Amgen’s interpretation of the BPCIA is also contrary to the law’s purpose that patent litigation should be resolved early and not delay biosimilar competition. The brief labeled as “fantasy” Amgen’s warning that Sandoz’s BPCIA interpretation would lead to chaos, causing attorneys for RPSs to rush into litigation prior to knowing what patents were being infringed and when the product was launching.
Amgen must submit its final brief to the Court by April 14, 2017. Oral arguments are scheduled for April 26, 2017, with a decision expected by the end of June.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.